kabutan

KOBAYASHI PHARMA, Jan-Sep (Cumulative 3Q) Ordinary Profit Decreases by 28%

Tue Nov 11, 2025 3:30 pm JST Earnings

4967 KOBAYASHI PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Earnings Report

KOBAYASHI PHARMACEUTICAL CO.,LTD. <4967> [TSE Prime] announced its financial results after the market closed on November 11th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending December 2025 (January to September) decreased 27.9% from the same period last year to 12.9 billion yen. However, Progress toward the full-year plan of 15.3 billion yen was 84.5%, also surpassing the five-year average of 73.2%.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the October to December period (4Q) is expected to significant drop 73.5% from the same period last year to 2.37 billion yen.

In the most recent three-month period, from July to September (3Q), the consolidated ordinary profit decreased to 5.68 billion yen, a 24.1% decrease compared to the same period last year. The operating profit margin significantly dropped from 18.2% in the same period last year to 11.3%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Jan - Sep, 2023 119,115 19,387 20,837 15,498 203.6 76.2 Nov 7, 2023 J-GAAP
Jan - Sep, 2024 114,459 16,976 17,921 5,344 71.9 66.7 Nov 8, 2024 J-GAAP
Jan - Sep, 2025 112,038 11,495 12,930 6,809 91.6 84.5 Nov 11, 2025 J-GAAP
YoY -2.1% -32.3% -27.9% +27.4% +27.4%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2024 92,464 15,389 16,427 8,631 116.1 59 Feb 10, 2025 J-GAAP
Jul - Dec, 2025 Guidance 101,982 7,352 8,055 7,333 98.7 60 Aug 5, 2025 J-GAAP
YoY +10.3% -52.2% -51.0% -15.0% -15.0%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2023 173,455 25,780 27,330 20,338 268.2 101 Feb 9, 2024 J-GAAP
Dec, 2024 165,600 24,860 26,861 10,067 135.4 102 Feb 10, 2025 J-GAAP
Dec, 2025 Guidance 171,000 14,000 15,300 10,500 141.3 104 Feb 10, 2025 J-GAAP
YoY +3.3% -43.7% -43.0% +4.3% +4.3%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 41,323 7,505 7,487 3,908 52.6 18.2 Nov 8, 2024 J-GAAP
Oct - Dec, 2024 51,141 7,884 8,940 4,723 63.5 15.4 Feb 10, 2025 J-GAAP
Jan - Mar, 2025 32,607 2,535 2,401 1,624 21.9 7.8 May 9, 2025 J-GAAP
Apr - Jun, 2025 36,411 4,113 4,844 1,543 20.8 11.3 Aug 5, 2025 J-GAAP
Jul - Sep, 2025 43,020 4,847 5,685 3,642 49.0 11.3 Nov 11, 2025 J-GAAP
YoY +4.1% -35.4% -24.1% -6.8% -6.8%

Related Articles